0.082
0.00 (0.00%)
| 前收盘价格 | 0.082 |
| 收盘价格 | 0.082 |
| 成交量 | 16,504 |
| 平均成交量 (3个月) | 19,971 |
| 市值 | 2,677,021 |
| 价格/销量 (P/S) | 0.330 |
| 股市价格/股市净资产 (P/B) | 3.84 |
| 52周波幅 | |
| 利润日期 | 28 Aug 2024 - 2 Sep 2024 |
| 营业毛利率 | -106.79% |
| 营业利益率 (TTM) | -56.43% |
| 稀释每股收益 (EPS TTM) | -0.180 |
| 季度收入增长率 (YOY) | 137.00% |
| 流动比率 (MRQ) | 0.090 |
| 营业现金流 (OCF TTM) | -2.45 M |
| 杠杆自由现金流 (LFCF TTM) | -1.33 M |
| 资产报酬率 (ROA TTM) | -109.93% |
| 股东权益报酬率 (ROE TTM) | -2,804.87% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Diagnostics & Research (AU) | 混合的 | 混合的 |
| Diagnostics & Research (全球的) | 混合的 | 混合的 | |
| 股票 | IMAGIONBIO FPO [IBX] | - | - |
AIStockmoo 评分
| 分析师共识 | 0.0 |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | -2.5 |
| 平均 | -0.50 |
|
Imagion Biosystems Ltd operates in the field of non-invasive detection of specific solid tumor cancers by use of magnetic nanoparticles. Its principal continuing activities consisted of Nanotechnology; Biotechnology; Cancer Diagnostics; and Medical Imaging using Magnetic Resonance and Superparamagnetic Relaxometry. The company only operating segment - Research and Development. Its principal business activities consist of nanotechnology, biotechnology, cancer diagnostics, and medical imaging using Superparamagnetic Relaxometry. In addition, the company is engaged in the research and development of its clinical phase lead product which is intended for the detection and staging of metastatic HER2 breast cancer. |
|
| 部门 | Healthcare |
| 行业 | Diagnostics & Research |
| 投资方式 | Small Growth |
| 内部持股比例 | 4.43% |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合